Chemotherapy for metastatic bladder cancer.
This paper reviews the current status of systemic chemotherapy in the management of advanced and metastatic urothelial cancer. The activity of a number of single agents and combination drug regimens is discussed, and the small number of randomised-controlled studies available is also considered. Prognostic factors for response and survival, particularly long-term survival after systemic chemotherapy, are also reviewed. Special consideration is given to the role of systemic chemotherapy as a precursor to surgery (or radiotherapy) in locally advanced disease that is initially considered incurable. Therapeutic options for patients unable to tolerate cisplatin owing to renal impairment or other comorbidities are explored. Future directions are explored, including the role of molecular phenotyping in providing prognostic information, indicators of the likely success of conventional therapeutic measures and the development of specific targeted therapies.
Roberts
J T
JT
Northern Centre for Cancer Treatment, Newcastle General Hospital, Newcastle upon Tyne, UK. trevor.roberts@nuth.nhs.uk
D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D014408:Biomarkers, Tumor; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000473:pathology*; D002945:Cisplatin / Q000008:administration & dosage; D015897:Comorbidity; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D007674:Kidney Diseases / Q000150:complications / Q000209:etiology; D008727:Methotrexate / Q000008:administration & dosage; D009362:Neoplasm Metastasis; D010641:Phenotype; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D013534:Survival; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D014747:Vinblastine / Q000008:administration & dosage
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D014747:Vinblastine; D004317:Doxorubicin; D002945:Cisplatin; D008727:Methotrexate